The justices are set to hear Hikma v. Amarin, a battle over drug patents that could raise costs for patients and change the way generic companies do business.
Health Care Costs
Posted inCost of Care
High Health Care Costs Are Fueling a New Fight Over Old Laws
The White House wants states to drop certificate of need laws in hopes of lowering health care costs. Researchers and state leaders are split.
Posted inCost of Care
Inside the Urgent Care Boom
Our friends at The Pulse from WHYY explore the economics behind the rise of urgent care and how it’s changing American medicine.
Posted inInsurance
‘It Sucks’: Spiking Health Insurance Costs Hit Small Businesses
An employer in Chicago describes how another year of rising premiums forced her to consider dropping her workers’ insurance.
Posted inNews & Announcements
Letter from the Editor: A Consequential Year
A message from Tradeoffs founder and executive editor Dan Gorenstein.
Posted inInsurance
Rising Costs, Fewer Choices: What’s Up with Medicare Drug Plans?
Facing mounting financial pressures, insurance companies are changing the prescription drug coverage available to many consumers in Medicare Part D.
Posted inCost of Care
What Would Actually Lower Drug Prices in America? Experts Weigh In
Some of America’s top scholars on prescription drug pricing outline steps the Trump administration could take to make medicines more affordable.
Posted inCost of Care
Will Trump’s Prescription Drug Deals Really Lower Prices?
Facing unprecedented pressure from the Trump administration, some of the world’s top drugmakers promise to cut prices. But experts say the savings might not be what they seem.
Posted inInsurance
Watch: Obamacare Subsidies at a Crossroads
Experts discuss what the loss of Obamacare subsidies means to patients and costs within the ACA insurance marketplace.
Posted inCost of Care
Obamacare Premiums Are About to Soar. How’d We Get Here?
Federal subsidies for Affordable Care Act health plans are set to shrink next year. Many shoppers are expected to be priced out, leaving those who stay with higher premiums. The dynamic that threatens to leave markets with fewer and more expensive options as insurers exit, too. How did we get here?